FindTrial
Sign In

A study to know the effects of a chemotherapy medicine named Gemcitabine plus Docetaxel combination in patients of recurrent or advanced soft tissue sarcoma

Outcomes of gemcitabine-docetaxel combination in patients of recurrent or metastatic soft tissue sarcoma: a retrospective analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/08/015291
Enrollment
34
Registered
2018-08-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Recurrent of metastatic soft tissue sarcoma

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age 18-60 years 2) Histologically/Cytologically proven metastatic/advanced(recurrent) STS 3) Previously treated with at least one first-line regimen in neo-adjuvant or advanced or metastatic setting and either progressed on chemotherapy or recurred to an advanced stage, after failure of/intolerance to first line systemic chemotherapy 4)Received at least 3 cycles of Gemcitabine-Docetaxel combination as second line therapy in the advanced(recurrent) or metastatic settling

Exclusion criteria

Exclusion criteria: Incomplete data on EMR or case records

Design outcomes

Primary

MeasureTime frame
To study the outcomes of gemcitabine-docetaxel combination as second-line systemic chemotherapy in patients of recurrent or metastatic soft tissue sarcomasTimepoint: Post 3 cycles of Gemcitabine plus Docetaxel—

Secondary

MeasureTime frame
To study the toxicity profile, tolerance, progression free Survival(PFS), and overall survival(OS) in the study population Timepoint: Post 3 cycles of Gemcitabine plus Docetaxel—

Countries

India

Contacts

Public ContactYogesh Kembhavi

Tata Memorial Hospital

dr_jyotibajpai@yahoo.co.in02224177287

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026